XBiotech Inc
Company Profile
Business description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
stocks
Undervalued ASX share upgrades guidance
stocks
ASX major bank drives strong quarterly profit
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.00 | 79.70 | 0.88% |
| CAC 40 | 8,428.07 | 22.01 | 0.26% |
| DAX 40 | 25,338.21 | 22.82 | -0.09% |
| Dow JONES (US) | 52,531.97 | 321.89 | 0.62% |
| FTSE 100 | 10,850.19 | 68.44 | 0.63% |
| HKSE | 25,310.85 | 103.67 | 0.41% |
| NASDAQ | 24,602.99 | 329.09 | -1.32% |
| Nikkei 225 | 62,364.92 | 2,566.27 | -3.95% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,386.49 | 26.69 | -0.36% |
| S&P/ASX 200 | 8,947.80 | 85.60 | 0.97% |
| SSE Composite Index | 3,813.31 | 44.93 | -1.16% |